This year’s annual congress of the SNMMI (Society of Nuclear Medicine and Molecular Imaging), held in June in Philadelphia, was Global Morpho Pharma’s first appearance at an international event. To mark the occasion, the company finalised a new partnership deal with Spectron LLC. Spectron will thus become our primary partner in a new international structure whose contours are still being finalised, with responsibility for the pharmaceutical transformation, distribution and radiolabelling (for therapeutic purposes) of non carrier-added Lutetium-177 and Actinum-225 products in the United States. Spectron is in the process of preparing a DMF (Drug Master File), a preliminary step on the path to market approval.
Global Morpho Pharma is a new radiopharmaceutical expert from France, founded to meet the market demand for high-quality radionuclides suitable for medical applications, with an initial focus on non carrier-added Lutetium-177 and Actinum-225 products. During the congress Spectron, a leading specialist in advanced radiopharmaceuticals, announced that the Lutetium radioisotope will soon be commercially available. Highly promising clinical trials in the United States and Europe have highlighted the great potential of this isotope for use in the treatment of prostate, kidney and pancreatic cancers. Getting in on the ground floor with Lutetium is a highly strategic move, as demand for this radioisotope is set to grow exponentially in the coming years. The development of these new treatments at the cutting edge of nuclear medicine will further cement Spectron’s leading position in the radiopharmaceutical sector, while establishing Global Morpho Pharma’s reputation as a global supplier of radionuclides for therapeutic purposes, with a worldwide distribution network.